SCHEMBL4864795

SCHEMBL4864795

COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc(C=NO)n3C(C)C)n2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 19/20 0.75
CDK4 P11802 9/20 0.75
CDK1 P06493 2/20 0.54
KCNH2 Q12809 2/20 0.51
CCNT1 O60563 1/20 0.51
CCNB1 P14635 1/20 0.51
CSNK2A2 P19784 1/20 0.51
CCNA2 P20248 1/20 0.51
CCND1 P24385 1/20 0.51
CCNE1 P24864 1/20 0.51
CCND3 P30281 1/20 0.51
MAPK8 P45983 1/20 0.51
MAPK9 P45984 1/20 0.51
CSNK1A1 P48729 1/20 0.51
CSNK1D P48730 1/20 0.51
GSK3A P49840 1/20 0.51
GSK3B P49841 1/20 0.51
CDK7 P50613 1/20 0.51
CDK9 P50750 1/20 0.51
CCNH P51946 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4864992 0.90 CDK2 (0.80) CDK2CDK4CDK1KCNH2CCNT1
SCHEMBL5102441 0.89 CDK2 (0.77) CDK2CDK4CDK1KCNH2CCNT1
SCHEMBL5102443 0.89 CDK2 (0.77) CDK2CDK4CDK1KCNH2CCNT1
SCHEMBL23752538 0.86 CDK2 (1.00) CDK2CDK4CDK1KCNH2CCNT1
SCHEMBL5915648 0.84 CDK2 (0.81) CDK2CDK4CDK1KCNH2CCNT1
SCHEMBL4864789 0.84 CDK2 (0.77) CDK2CDK4CDK1KCNH2CCNT1
SCHEMBL5915733 0.84 CDK2 (0.77) CDK2CDK4CDK1KCNH2CCNT1
SCHEMBL5915831 0.83 CDK2 (0.79) CDK2CDK4CDK1KCNH2CCNT1
SCHEMBL5109334 0.80 CDK2 (0.75) CDK2CDK4CDK1
SCHEMBL5092267 0.80 CDK2 (0.73) CDK2CDK4CDK1KCNH2CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7427626-B2 2-Anilino-4-(imidazol-5-yl)-pyrimidine derivatives and their use as cdk (cdk2) inhibitors ASTRAZENECA AB (SE) 2008-09-23 US disclosed